SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 135, Issue 9, Pages 2223-2231
Publisher
Wiley
Online
2014-03-26
DOI
10.1002/ijc.28865
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects
- (2015) Quteba Ebrahem et al. Oncotarget
- Aerosolised 5-azacytidine suppresses tumour growth and reprogrammes the epigenome in an orthotopic lung cancer model
- (2013) M D Reed et al. BRITISH JOURNAL OF CANCER
- Immunomodulatory activity of SGI-110, a 5-aza-2′-deoxycytidine-containing demethylating dinucleotide
- (2012) Sandra Coral et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Epigenetic Resensitization to Platinum in Ovarian Cancer
- (2012) D. Matei et al. CANCER RESEARCH
- Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine
- (2011) D. Lavelle et al. BLOOD
- HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL
- (2011) M. Kalac et al. BLOOD
- Combination Therapy with Vidaza and Entinostat Suppresses Tumor Growth and Reprograms the Epigenome in an Orthotopic Lung Cancer Model
- (2011) Steven A. Belinsky et al. CANCER RESEARCH
- Preclinical studies on histone deacetylase inhibitors as therapeutic reagents for endometrial and ovarian cancers
- (2011) Brahma N Singh et al. Future Oncology
- Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non-Small Cell Lung Cancer
- (2011) R. A. Juergens et al. Cancer Discovery
- 5-azacytidine treatment reorganizes genomic histone modification patterns
- (2010) Vitalina M. Komashko et al. Epigenetics
- S110, a 5-Aza-2'-Deoxycytidine-Containing Dinucleotide, Is an Effective DNA Methylation Inhibitor In vivo and Can Reduce Tumor Growth
- (2010) J. C. Chuang et al. MOLECULAR CANCER THERAPEUTICS
- Targeting DNA Methylation
- (2009) J.-P. J. Issa et al. CLINICAL CANCER RESEARCH
- A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas
- (2008) L. Gore et al. CLINICAL CANCER RESEARCH
- Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models
- (2008) Shuzhen Liu et al. MOLECULAR CANCER THERAPEUTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started